title: Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - YES.
authors.affiliation: University of Ottawa-Neuroscience, Ottawa, ON, Canada mfreedman@toh.ca.
authors.forename: Mark
authors.initials: M
authors.lastname: Freedman
authors.affiliation: Regenerative Medicine, Ottawa Hospital Research Institute-Medicine, Ottawa, ON, Canada.
authors.forename: Harold L
authors.initials: HL
authors.lastname: Atkins
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000276:immunology*; D006801:Humans; D009103:Multiple Sclerosis / Q000628:therapy*; D012306:Risk; D014182:Transplantation, Autologous